Pei-Ling Chu

6.1k total citations
11 papers, 184 citations indexed

About

Pei-Ling Chu is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Health, Toxicology and Mutagenesis. According to data from OpenAlex, Pei-Ling Chu has authored 11 papers receiving a total of 184 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Molecular Biology and 2 papers in Health, Toxicology and Mutagenesis. Recurrent topics in Pei-Ling Chu's work include Diabetes Treatment and Management (5 papers), Diabetes Management and Research (5 papers) and Metabolism, Diabetes, and Cancer (3 papers). Pei-Ling Chu is often cited by papers focused on Diabetes Treatment and Management (5 papers), Diabetes Management and Research (5 papers) and Metabolism, Diabetes, and Cancer (3 papers). Pei-Ling Chu collaborates with scholars based in United States, United Kingdom and China. Pei-Ling Chu's co-authors include Weichung Joe Shih, Yong Lin, Mark D. Shepherd, Anuj Bhargava, David S. Oyer, Jason Brett, Mohammed Abdul Majeed, Xiaolan Zhang, Niklas Rye Jørgensen and Ning Li and has published in prestigious journals such as Journal of Clinical Oncology, The Science of The Total Environment and Diabetes Care.

In The Last Decade

Pei-Ling Chu

11 papers receiving 176 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pei-Ling Chu United States 9 82 34 34 29 27 11 184
Jianmei Yang China 8 87 1.1× 12 0.4× 10 0.3× 37 1.3× 28 259
Zhila Semnani‐Azad Canada 10 92 1.1× 42 1.2× 7 0.2× 51 1.8× 4 0.1× 19 272
Kazuhide Ishikura Japan 6 88 1.1× 33 1.0× 13 0.4× 41 1.4× 12 203
Nameer Al‐Yousif Canada 6 24 0.3× 9 0.3× 2 0.1× 27 0.9× 7 0.3× 10 150
Mei Kuen Tang United States 9 13 0.2× 14 0.4× 26 0.8× 60 2.1× 2 0.1× 13 199
Evangelia E. Tsakiridis Canada 8 46 0.6× 25 0.7× 28 0.8× 76 2.6× 1 0.0× 14 204
Linglin Xie United States 10 38 0.5× 24 0.7× 22 0.6× 86 3.0× 23 268
Yoshiki Tsuboi Japan 11 21 0.3× 26 0.8× 19 0.6× 132 4.6× 3 0.1× 38 263
Randi Grøn Denmark 8 217 2.6× 52 1.5× 4 0.1× 113 3.9× 17 0.6× 14 302
Haesook Min South Korea 11 43 0.5× 9 0.3× 13 0.4× 35 1.2× 2 0.1× 15 257

Countries citing papers authored by Pei-Ling Chu

Since Specialization
Citations

This map shows the geographic impact of Pei-Ling Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pei-Ling Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pei-Ling Chu more than expected).

Fields of papers citing papers by Pei-Ling Chu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pei-Ling Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pei-Ling Chu. The network helps show where Pei-Ling Chu may publish in the future.

Co-authorship network of co-authors of Pei-Ling Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Pei-Ling Chu. A scholar is included among the top collaborators of Pei-Ling Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pei-Ling Chu. Pei-Ling Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Califano, Raffaele, Antonio Passaro, Ana Blasco, et al.. (2025). Amivantamab plus chemotherapy vs chemotherapy in EGFR -mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.. Journal of Clinical Oncology. 43(16_suppl). 8639–8639. 1 indexed citations
2.
Li, Ning, et al.. (2018). Therapeutic Effect of HGF on NASH Mice Through HGF/c-Met and JAK2-STAT3 Signalling Pathway. Annals of Hepatology. 17(3). 501–510. 23 indexed citations
3.
Rodbard, Helena W., Ildiko Lingvay, John H. Reed, et al.. (2016). Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5). Canadian Journal of Diabetes. 40(5). S41–S42. 21 indexed citations
4.
Jennum, Poul, Kirstine L. Stender-Petersen, Rasmus Rabøl, et al.. (2015). The Impact of Nocturnal Hypoglycemia on Sleep in Subjects With Type 2 Diabetes. Diabetes Care. 38(11). 2151–2157. 16 indexed citations
5.
Shepherd, Mark D., et al.. (2012). Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial). Current Medical Research and Opinion. 28(7). 1203–1211. 4 indexed citations
6.
7.
Oyer, David S., et al.. (2009). A1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial). The American Journal of Medicine. 122(11). 1043–1049. 36 indexed citations
8.
Majeed, Mohammed Abdul, et al.. (2009). Characterizing relationships between personal exposures to VOCs and socioeconomic, demographic, behavioral variables. Atmospheric Environment. 43(14). 2296–2302. 25 indexed citations
9.
Hoelscher, David, Pei-Ling Chu, & William H. Lyness. (2008). Fixed-Dose Combination Tablet of Repaglinide and Metformin is Bioequivalent to Concomitantly Administered Individual Tablets of Repaglinide and Metformin. Clinical Drug Investigation. 28(9). 573–582. 8 indexed citations
10.
Chu, Pei-Ling, Yong Lin, & Weichung Joe Shih. (2008). Unifying CRM and EWOC designs for phase I cancer clinical trials. Journal of Statistical Planning and Inference. 139(3). 1146–1163. 27 indexed citations
11.
Hore, Paromita, Valerie Zartarian, Jianping Xue, et al.. (2005). Children's residential exposure to chlorpyrifos: Application of CPPAES field measurements of chlorpyrifos and TCPy within MENTOR/SHEDS-Pesticides model. The Science of The Total Environment. 366(2-3). 525–537. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianmei Yang Breakdown of academic impact, for papers by Zhila Semnani‐Azad Breakdown of academic impact, for papers by Kazuhide Ishikura Breakdown of academic impact, for papers by Nameer Al‐Yousif Breakdown of academic impact, for papers by Mei Kuen Tang Breakdown of academic impact, for papers by Evangelia E. Tsakiridis Breakdown of academic impact, for papers by Linglin Xie Breakdown of academic impact, for papers by Yoshiki Tsuboi Breakdown of academic impact, for papers by Randi Grøn Breakdown of academic impact, for papers by Haesook Min
Rankless by CCL
2026